Malignant degeneration of Barrett's esophagus: clinical point of view.

Malignant degeneration of Barrett's esophagus: clinical point of view. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Malignant degeneration of Barrett's esophagus: clinical point of view. Abstract Text:

H J Stein,M Feith,J R Siewert,

The incidence of adenocarcinoma of the distal esophagus is increasing at an alarming rate. Intestinal metaplasia in the distal esophagus, i.e. Barrett's esophagus, has been identified as the single most important risk factor for these tumors. Barrett's esophagus develops as a consequence of chronic mucosal injury in up to 10% of patients with long-lasting gastroesophageal reflux disease. Experimental and clinical data indicate that adenocarcinoma of the distal esophagus is a direct consequence of mixed (i.e., acid and bile) reflux into the esophagus. Interestingly, Helicobacter pylori infection of the stomach appears to exert a protective effect against the development of esophageal adenocarcinoma. Neither aggressive medical acid suppression nor antireflux surgery can induce a predictable regression of Barrett's esophagus or exert a protective effect against its malignant degeneration. Endoscopic ablation of Barrett's esophagus, although appealing, currently constitutes a potentially dangerous procedure without proven benefit for the patient. Since the development of Barrett's adenocarcinoma follows a multistep process from metaplasia through increasingly severe grades of dysplasia, close endoscopic surveillance with extensive biopsies currently remains the only means to identify patients at risk for malignant degeneration and detect esophageal adenocarcinoma at an early and curable stage.

Malignant degeneration of Barrett's esophagus: clinical point of view. Publishing Authors By Initials

HJ Stein,M Feith,JR Siewert,

For similar tissues: membranes: mucous membrane research abstracts see: tissues: membranes: mucous membrane research

PUBMED ID PMID:

MEDLINE DATE:

Malignant degeneration of Barrett's esophagus: clinical point of view. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 155

Page Numbers: 42-53

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 2000

Malignant degeneration of Barrett's esophagus: clinical point of view. Information

Number of References: 42

LANGUAGE: eng

NlmUniqueID: 44671

Malignant degeneration of Barrett's esophagus: clinical point of view. Keywords Mesh Terms:

KEYWORDS: Mucous Membrane

MESH TERMS: pathology

Chemical & Substance for Abstract: Malignant degeneration of Barrett's esophagus: clinical point of view. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Malignant degeneration of Barrett's esophagus: clinical point of view.

AFFILIATION: Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der TU München, Germany.

Country: GERMANY

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Malignant degeneration of Barrett's esophagus: clinical point of view Related Publications

• Detection of circulating tumor cells in blood using an optimized density gradient centrifugation.
• Fulminate intracardiac thrombosis associated with Budd-Chiari-syndrome and inferior vena cava thrombosis.
• Histopathological response after preoperative radiochemotherapy in rectal carcinoma is associated with improved overall survival.
• Malignant degeneration of Barrett's esophagus: clinical point of view.
• Malignant progression in Barrett's esophagus: pathology and molecular biology.
• Management of early esophageal cancer.
• Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer.
• Risk analysis in esophageal surgery.
• Stent implantation as a treatment option in patients with thoracic anastomotic leaks after esophagectomy.
• Telomere length and hTERT expression in patients with colorectal carcinoma.
• [Ambulatory surgery at the surgical clinic and polyclinic of the Munich Technical University]
• [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus]
• [Combined therapy of inoperable esophageal cancer]
• [Counter-indicated, unnecessary and superfluous surgical methods]
• [Diagnostic procedure in postoperative complications]
• [Extent of radical surgery in cardia carcinoma--esophagectomy or gastrectomy?]
• [Gastrointestinal hormones and lower esophageal sphincter]
• [Motility disorders as a pathogenetic principle: esophagus and cardia]
• [Motility disorders as a pathogenetic principle: introduction]
• [Possibilities of telecommunications in surgery]
• [Preoperative risk and postoperative follow-up in surgery of esophageal carcinoma]
• [Principles of radical surgery]
• [R1 resection in the surgery of upper gastrointestinal tumors : Relevance and therapeutic consequences.]
• [Reflux esophagitis from the surgical viewpoint]
• [Severe reflux esophagitis--conservative versus operative treatment. The surgical viewpoint]
• [Technical requirements and possibilities of teleconsultation in laparoscopic interventions]
• [The quality of life of patients with stomach and esophageal cancers]
• [Therapy of esophageal diverticula]
• [Trends in gastroenterologic intensive care medicine: suppurative cholangitis--surgery]
• [Value of clinical and experimental results for general practice in esophageal surgery]